Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy

This study has been completed.

First Received on November 2, 1999. Last Updated on June 23, 2005 History of Changes

Sponsor:	Pfizer
Information provided by:	NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:	NCT00002038

Purpose

The primary purpose of this protocol is to provide fluconazole for the treatment of individual patients who require therapy for serious or life-threatening systemic fungal infection, who have failed on conventional antifungal therapy or have had unacceptable reactions to conventional antifungal therapy, and who are ineligible for other established fluconazole clinical trial protocols.

Condition	Intervention
Candidiasis Mycoses HIV Infections	Drug: Fluconazole

Study Type:	Interventional
Study Design:	Primary Purpose: Treatment
Official Title:	Non-Comparative Study of Fluconazole in Patients With Serious Mycoses and Who Cannot Be Treated With Conventional Antifungal Therapy

Resource links provided by NLM:

Genetics Home Reference related topics: complement factor I deficiency

MedlinePlus related topics: Fungal Infections HIV/AIDS Yeast Infections

Drug Information available for: Fluconazole

U.S. FDA Resources

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Exclusion Criteria

Co-existing Condition:

A patient will be excluded if he/she has previously had an unacceptable adverse effect due to fluconazole.

AMENDED:

900207 Open only to unapproved indications and/or age ranges.
Original design:
Patients with clinically established serious or life-threatening systemic fungal disease will be considered if conventional fungal therapy is not an acceptable alternative. Unacceptability of conventional therapy is defined as:
Failure of conventional therapy to control or eradicate infection after appropriate trial(s) of generally accepted regimen(s).
Serious and unacceptable untoward reaction(s) to conventional antifungal therapy.
OR A major contraindication to the use of conventional antifungal therapy.
The patient must be ineligible or have no access to other established fluconazole investigational protocols. The final judgment of patient acceptability for inclusion lies with the Pfizer Clinical Monitor.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00002038

Locations

United States, Connecticut
Pfizer Central Research
Groton, Connecticut, United States, 06340

Sponsors and Collaborators

Pfizer

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00002038 History of Changes
Other Study ID Numbers:	012C, 056-152
Study First Received:	November 2, 1999
Last Updated:	June 23, 2005
Health Authority:	United States: Food and Drug Administration

Keywords provided by NIH AIDS Clinical Trials Information Service:

Mycoses
Drugs, Investigational
Fluconazole

Additional relevant MeSH terms:

HIV Infections
Acquired Immunodeficiency Syndrome
Candidiasis
Mycoses
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes

Immune System Diseases
Slow Virus Diseases
Antifungal Agents
Fluconazole
Anti-Infective Agents
Therapeutic Uses
Pharmacologic Actions
14-alpha Demethylase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on February 09, 2012